We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 104% below its sector, cheaper than its peers on earnings.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save LASA.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
